Gossamer Bio Inc GOSS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Gossamer Bio, Inc. Announces Determination of Conversion Rate for 7.50% Convertible Senior Secured First Lien Notes due 2030 and Exercise Price for Purchase Warrants
-
Gossamer Bio, Inc. Announces Final Tender Results for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes
-
Gossamer Bio, Inc. Announces Early Tender Results and Early Settlement for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes
-
Gossamer Bio, Inc. Announces Extension of Early Tender Date for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes
-
CLASS ACTION DEADLINE TONIGHT: Gossamer Bio (GOSS) Investors Who Suffered Losses Encouraged to Contact Faruqi & Faruqi Before June 1, 2026 Securities Class Action Deadline
-
GOSS Investors Have Opportunity to Lead Gossamer Bio, Inc. Securities Fraud Lawsuit with the Schall Law Firm
-
GOSS DEADLINE ALERT: Hagens Berman Alerts Gossamer Bio (GOSS) Investors to Today's Lead Plaintiff Deadline in Securities Class Action
-
Gossamer Bio, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - GOSS
Trading Information
- Previous Close Price
- $0.17
- Day Range
- $0.14–0.17
- 52-Week Range
- $0.14–3.87
- Bid/Ask
- $0.15 / $0.15
- Shares Outstanding
- 488.85M
- Market Cap
- $70.44M
- Volume/Avg
- 1M / 13M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 0.60
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension).
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 162
- Website
- https://www.gossamerbio.com
Valuation
|
Metric
|
GOSS
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 0.60 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
GOSS
|
|---|---|
Quick Ratio | 1.92 |
Current Ratio | 2.20 |
Interest Coverage | −15.60 |
Quick Ratio
GOSS
Profitability
|
Metric
|
GOSS
|
|---|---|
Return on Assets (Normalized) | −76.82% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | −125.54% |
Return on Assets
GOSS
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|@dGJKZ | LOCK|Ckz&K | $122B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|X<&hb$c | LOCK|Wt&J! | $70B | |||
| argenx SE ADR
ARGX
| LOCK|jG%^sT | LOCK|%b | $54B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|n%Dql^& | LOCK|@gJrD | $38B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|@TR!P#H | LOCK|%@ | $36B | |||
| Moderna Inc
MRNA
| LOCK|Y>NJYpL | LOCK|#d | $27B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|KN%&q@! | LOCK|bzgF | $25B | |||
| Incyte Corp
INCY
| LOCK|s^JpcYT | LOCK|^@> | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|yht!%d> | LOCK|@! | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|p^&vV& | LOCK|mw | $16B |
United States